Oral GLP-1 pills: how orforglipron and danuglipron compare

TL;DR

A 2025 review of eight trials found the two oral GLP-1 pills are not equal: orforglipron drove about 6.3 kg of weight loss versus danuglipron's 2.2 kg, though their blood-sugar effects were far closer. The pills are real, but which one you get matters, and short early trials still cannot rule out the rare safety problems that decide a drug's future.

The pill era of GLP-1 medications has arrived. Orforglipron, the first oral small-molecule GLP-1, reached the market in 2026, and for anyone who dreads a weekly injection that is a genuine shift. But "a GLP-1 in a pill" is not one single thing, and a 2025 meta-analysis makes the gap between the two leading oral candidates hard to ignore.

What these pills actually are

Ozempic, Wegovy and the tirzepatide brands (Mounjaro and Zepbound) are peptides. They are fragile in the gut, which is why they are injected. Orforglipron and danuglipron are different animals: small-molecule, non-peptide drugs that survive digestion, so they can be swallowed as a daily tablet with no needles and no cold storage. That is the whole promise of the oral class - the same appetite-quieting GLP-1 pathway, delivered by a pill you can keep in a drawer instead of a fridge.

There is already an oral form of semaglutide too, but it is a peptide that needs an empty stomach, a small sip of water, and a 30-minute wait before eating. The appeal of the small-molecule pills is that orforglipron, in its trials, worked without those food-timing rules. Two companies led this small-molecule race: Eli Lilly developed orforglipron, and Pfizer developed danuglipron. On paper both are oral GLP-1 drugs, and coverage tends to lump them together. The data say that is a mistake.

The weight-loss gap was large

Researchers pooled eight randomised controlled trials covering 1,454 people with type 2 diabetes or obesity, published in Frontiers in Endocrinology in late 2025. The weight-loss difference between the two pills was not subtle:

• Orforglipron: about 6.28 kg lost (roughly 14 lb), 95% confidence interval -8.45 to -4.11 kg
• Danuglipron: about 2.17 kg lost (roughly 5 lb), 95% confidence interval -3.10 to -1.23 kg

That is close to three times more weight lost on orforglipron. For a reader deciding whether a pill is worth waiting for, that spread is the real headline: the oral category as a whole tells you very little, because the two front-runners landed in completely different places. One caveat belongs right next to those numbers. These were early trials, most running 36 weeks or less, so they capture the first several months of use, not a year or two. The direction is clear; the exact figures will shift as longer studies report.

Why one pill pulled so far ahead

Despite the shared "oral GLP-1" label, these are structurally different molecules that engage the receptor differently, and their dosing reflected that. Danuglipron was pushed across a wide range up to 200 mg twice daily; orforglipron was dosed from 2 to 45 mg once daily and still delivered more weight loss. In plain terms, orforglipron got more appetite suppression out of a simpler daily dose. Worth keeping in mind: this review pooled results across separate trials rather than testing the two pills directly against each other in the same room, the trials varied in their background treatments, and every one was funded by industry. That makes the ranking believable but not a precise photo finish.

On blood sugar, the two were much closer

Weight is only one job these drugs do. On glucose control, the pills were nearly matched:

• HbA1c (a roughly three-month blood-sugar average): orforglipron -1.02%, danuglipron -0.90%
• Fasting plasma glucose: orforglipron -26.91 mg/dL, danuglipron -24.66 mg/dL

This is the nuance the weight numbers hide. If your main concern is type 2 diabetes and blood-sugar control, both pills did a broadly similar job. The gulf opens up on weight loss specifically, which tracks with how much appetite suppression each drug delivered. So "which pill is better" honestly depends on what you are treating, a point that applies across GLP-1 medications, not just the oral ones.

Side effects, and the safety question that decides a drug's future

Neither pill was gentle. Both were significantly linked to gastrointestinal problems - nausea, vomiting, diarrhoea, indigestion and constipation - the same GLP-1 side effects that injection users know well. The overall rate of treatment-emergent side effects was similar for the two (relative risk 1.22 for danuglipron, 1.26 for orforglipron versus comparators). Slowed gastric emptying does not care whether the drug arrived by needle or by mouth. If you want the fuller picture on how the drugs stack up here, we broke it down in which GLP-1 causes the most digestive side effects.

Dosing was one practical split. Danuglipron was given twice a day; orforglipron once a day. For a drug taken for years, a single daily tablet is easier to stay consistent with than a twice-daily one.

The more important story is what this meta-analysis could not see. The pooled trials found no liver-enzyme safety signal for danuglipron. Yet Pfizer announced in 2025 that it was ending danuglipron's development after a liver-enzyme elevation in a single trial participant. Both things are true at the same time, and that is exactly the limitation the study authors flagged: short trials with small numbers cannot reliably catch rare but serious events. A pooled "no signal" is reassuring for the common problems and close to meaningless for the rare ones. It is the clearest reason not to read an early meta-analysis as a final verdict on any new drug.

What this means if you are waiting for a pill

A few honest conclusions come out of this.

First, orforglipron is the oral small-molecule pill that actually reached patients, winning FDA approval in 2026, while danuglipron did not. If you have read about "the GLP-1 pill," orforglipron is almost certainly the one now available. Our explainer on Foundayo and orforglipron, what patients need to know covers how it is taken and who it suits.

Second, a pill is not automatically as strong as the shots. Orforglipron's roughly 6 kg in these trials is a real result, but the higher-dose injectables and tirzepatide still lead on raw weight loss. We laid out that ranking in which GLP-1 is best for you, what a new efficacy index shows. If avoiding needles is your deciding factor, a pill is now a serious option; if maximum weight loss is, the injections are still ahead. There is also that oral form of semaglutide, covered in our piece on the first oral Wegovy pill for weight loss.

Third, and this is the part the drug comparisons skip: an oral GLP-1 suppresses appetite just as an injection does, so it carries the same nutrition problem. When you eat far less, your intake of protein, iron, vitamin B12, vitamin D and other basics falls with it, and the delivery method changes nothing about that. GLP-1 Shield was built around exactly those gaps, and our guide to the GLP-1 supplement protocol, what to take and how much walks through covering them safely. The pill-versus-injection question and the nutrition question are two separate decisions, and getting the drug right does not settle the second one.

One last practical note. Both pills were studied mostly in shorter trials, and the questions that matter most over years - how much of the weight stays off, how the body adjusts, and how the rarer side effects behave - are still open. Orforglipron reaching approval means those answers will now come from real-world use rather than trials alone. The honest stance today is cautious optimism about the oral GLP-1 class, not a finished verdict on it.

Frequently asked questions

Is there a GLP-1 pill for weight loss now?

Yes. Orforglipron, an oral small-molecule GLP-1, reached the market in 2026 after FDA approval, and there is also an oral form of semaglutide. In a 2025 meta-analysis of eight trials, orforglipron produced about 6.28 kg of weight loss over trials lasting 36 weeks or less. Longer real-world data is still being gathered.

Is orforglipron as good as Ozempic or Wegovy?

Not quite on weight loss. Orforglipron's roughly 6 kg in early trials is meaningful, but higher-dose injectable semaglutide and tirzepatide have produced greater weight loss in their own trials. On blood-sugar control the gap is smaller. Orforglipron's main advantage is that it is a daily pill with no injection.

What happened to danuglipron, Pfizer's GLP-1 pill?

Pfizer announced in 2025 that it was ending danuglipron's development after a liver-enzyme elevation in one trial participant. In the pooled 2025 meta-analysis danuglipron also drove far less weight loss than orforglipron, about 2.17 kg versus 6.28 kg, though its effect on blood sugar was similar. It is not available.

Do oral GLP-1 pills cause fewer side effects than injections?

Not really. Both oral pills in the 2025 review were significantly linked to gastrointestinal side effects such as nausea, vomiting and constipation, the same issues injection users report. The pill format removes the needle, not the slowed digestion that drives most GLP-1 side effects.